<unk>  (EPP), also known as<unk>  17β-phenylpropionate and sold under the brand name Menformon Prolongatum, is an estrogen which is no longer marketed. It is an estrogen ester, specifically the C17β<unk>  ester of<unk> . EPP has been marketed in combination with<unk>  benzoate under the brand name Dimenformon Prolongatum in Europe and in combination with<unk>  benzoate, testosterone propionate, testosterone<unk> , and testosterone isocaproate under the brand names Mixogen, Estandron Prolongatum, and Lynandron Prolongatum (a balanced mixture of<unk>  and testosterone esters) in menopausal hormone therapy. Both of these medication combinations are long-acting injectables indicated in hormone replacement therapy for women in menopause. Dimenformon Prolongatum has also been investigated as a single injection, "morning after" post-coital contraceptive, and is additionally used as a component of hormone replacement therapy for transgender women. The pharmacokinetics of EPP in combination with<unk>  benzoate have been studied.
Estradiol phenylpropionate
Estradiol monopropionate
Estradiol propoxyphenylpropionate
Testosterone hexahydrobenzoate
Estradiol hexahydrobenzoate
Estradiol butyrylacetate
Estradiol diundecylate
Estradiol dibutyrate